APL-9796 / Apollo Therap - LARVOL DELTA

Anti‑ZIP12 mAb APL‑9796 Attenuates Fibrosis and Inflammation in Experimental Pulmonary Hypertension Rodent Model (ERS 2026) - "APL‑9796 was evaluated in vivo using the resiquimod–SU5416 (R‑SU) rat model, which recapitulates key features of Group 3 PH, including elevated pulmonary haemodynamics, perivascular inflammation and pulmonary fibrosis...Circulating pro‑inflammatory cytokines and chemokines, including CXCL1, CCL5, TNF‑α, CXCL10 and IL‑17, were also reduced. ConclusionsTargeting zinc homeostasis with APL‑9796 demonstrates potential as a disease‑modifying therapeutic strategy for Group 3 PH."

Preclinical • Cardiovascular • Fibrosis • Immunology • Inflammation • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • CXCL1 • CXCL10 • TIMP1 • TNFA • VIM

A Randomised, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous, Ascending Single Doses of AP13 in Healthy Adults (ANZCTR) - P1 | N=39 | Completed | Sponsor: Apollo Therapeutics | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

ViTAL-PH: A Trial of "APL-9796'' in Adults With Pulmonary Hypertension (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Apollo Therapeutics Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases

ViTAL-PH: A Trial of "APL-9796'' in Adults With Pulmonary Hypertension (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Apollo Therapeutics Ltd

New P2 trial • Cardiovascular • Hypertension • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases